John E. Bishop

Chief Technology Officer

Forma Therapeutics Holdings, Inc.Momenta Pharmaceuticals Inc Ardelyx, Inc.

Insider activity · 24 months0 buys4 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 1 saleMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 1 saleJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 2 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (4 ops.)

€91k

Latest filing published 25 Aug 2026 for Ardelyx, INC., €57k. Read the official filing

Filing timeline

BuySale

John E. Bishop

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

John E. Bishop: trading record in brief

John E. Bishop, listed as senior executive, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Ardelyx, Inc., Forma Therapeutics Holdings, Inc. and Momenta Pharmaceuticals Inc. Over a trading history stretching from 9 February 2016 to 21 August 2026, the count stands at 9 filings.

Every open-market trade on record is a sale: 4 sales worth €91k. Other entries cover 4 share grants. Since January 2026: no purchases and 4 sales on the market.

The record was last updated on 25 August 2026 with an open-market sale (€57k) in Ardelyx, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.